-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Xeris Biopharma Holdings, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2020 to Q2 2024.
- Xeris Biopharma Holdings, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $749K.
- Xeris Biopharma Holdings, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $482K.
- Xeris Biopharma Holdings, Inc. annual Income Tax Expense (Benefit) for 2023 was -$1.25M, a 12.3% increase from 2022.
- Xeris Biopharma Holdings, Inc. annual Income Tax Expense (Benefit) for 2022 was -$1.42M.
- Xeris Biopharma Holdings, Inc. annual Income Tax Expense (Benefit) for 2021 was $0.000.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)